방광암 진단 시장 - 전략적 인사이트와 예측(2026-2035년)

The Bladder Cancer Diagnostics Market is set to reach USD 9.42 billion in 2035, growing at a CAGR of 9.2 % from USD 4.26 billion in 2026.

The bladder cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward non-invasive testing, precision oncology, and personalized medicine. The market's evolution is characterized by the growing recognition that early detection and accurate molecular characterization are essential for improving patient outcomes, reducing healthcare costs, and enabling personalized treatment strategies. The convergence of advanced molecular technologies, including next-generation sequencing, liquid biopsy, and artificial intelligence-assisted pathology, is enabling faster, more sensitive, and increasingly accessible bladder cancer detection and monitoring. Healthcare systems worldwide are expanding diagnostic capabilities as bladder cancer incidence continues to rise due to aging populations, smoking prevalence, and occupational carcinogen exposure. The market is witnessing significant investment in urine-based biomarker assays, molecular diagnostics, and companion diagnostics, positioning bladder cancer diagnostics as a critical component of urological oncology and precision medicine.

Market Drivers

• The increasing global incidence of bladder cancer represents the primary driver for the bladder cancer diagnostics market. Rising disease burden creates sustained demand for diagnostic testing across screening, initial diagnosis, recurrence monitoring, and disease surveillance applications. Healthcare systems are expanding diagnostic capacity to support early detection and personalized treatment strategies. This requirement strengthens demand for diagnostic products across all modalities, resulting in sustained growth in bladder cancer diagnostic utilization. The rising adoption of non-invasive urine-based diagnostic technologies is further accelerating market growth through improved patient compliance. Non-invasive testing reduces patient discomfort and procedural risks associated with cystoscopy, encouraging broader screening and surveillance participation. Healthcare providers are incorporating urine-based biomarkers into diagnostic algorithms to improve early detection and monitoring. Diagnostic manufacturers are expanding urine-based assay portfolios to capture growing demand. The growing implementation of precision oncology and companion diagnostics is driving demand for molecular profiling and genomic testing. Precision medicine requires accurate molecular characterization to guide therapeutic decisions, creating sustained demand for advanced diagnostic technologies. Healthcare providers are expanding molecular testing capabilities to support personalized treatment strategies. Diagnostic manufacturers are developing specialized molecular and genomic testing solutions to support precision oncology applications. Technological advancements in molecular diagnostics and genomic profiling are improving diagnostic accuracy and clinical utility. Continuous innovation in NGS, liquid biopsy, and AI-assisted pathology is enhancing detection sensitivity and specificity. These advancements support broader clinical adoption and improved patient outcomes.

Market Restraints

• High costs associated with advanced molecular diagnostic testing limit adoption in resource-constrained healthcare systems. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited sensitivity of some conventional urine biomarker assays reduces clinical confidence and adoption. The performance limitations of certain biomarkers create challenges for clinical implementation. Stringent regulatory approval requirements for novel diagnostics increase development timelines and costs for manufacturers. The rigorous evidence requirements for new diagnostic products create barriers to market entry. Limited reimbursement for emerging genomic testing in certain markets restricts patient access and adoption.

Technology and Modality Insights

• The technology landscape is characterized by the growing importance of molecular diagnostics, liquid biopsy, and AI-enabled platforms. Cystoscopy remains the clinical gold standard for bladder cancer diagnosis and surveillance because of its high diagnostic accuracy. Urine-based diagnostics are experiencing rapid growth owing to increasing demand for non-invasive testing. Histopathology remains essential for definitive diagnosis and tumor characterization. Molecular diagnostics are expanding for genomic profiling and precision medicine applications. Imaging diagnostics continue supporting disease staging and treatment planning. The segment analysis reveals that immunohistochemistry remains widely utilized for tumor characterization and biomarker assessment. FISH technology continues supporting chromosomal abnormality detection. PCR-based assays enable sensitive molecular analysis. NGS is the fastest-growing technology due to expanding genomic profiling and personalized treatment selection. NMP22 remains one of the most commonly utilized urinary biomarkers for bladder cancer detection. UroVysion FISH has gained widespread clinical acceptance for recurrence monitoring. Recurrence monitoring represents a critical application because of the high recurrence rates associated with bladder cancer. Hospitals represent the leading end-user segment, with diagnostic laboratories and specialty urology clinics expanding testing capabilities. The integration of AI is becoming increasingly important as AI-assisted pathology and imaging diagnostics improve diagnostic accuracy and workflow efficiency.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized molecular, urology, and precision oncology providers. Roche develops molecular diagnostics, tissue diagnostics, companion diagnostics, and pathology solutions supporting precision diagnosis and treatment selection in bladder cancer. Abbott provides immunoassays, clinical chemistry systems, molecular diagnostics, and biomarker testing solutions supporting oncology diagnostics. Danaher offers genomics technologies, molecular diagnostics, laboratory automation, and precision medicine solutions for cancer diagnostics. Thermo Fisher Scientific develops PCR assays, sequencing platforms, molecular diagnostics, and precision oncology technologies supporting bladder cancer testing. Agilent specializes in pathology solutions, immunohistochemistry assays, genomic technologies, and companion diagnostics for oncology applications. QIAGEN develops molecular diagnostic assays, PCR technologies, sample preparation systems, and companion diagnostics supporting precision oncology. Illumina is a leading provider of NGS platforms enabling comprehensive genomic profiling and biomarker discovery. Bio-Rad develops digital PCR systems, molecular diagnostics, immunoassays, and laboratory quality control solutions for oncology testing. Companies are pursuing product portfolio expansion through innovation in urine-based biomarkers, liquid biopsy, and AI-enabled platforms. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Guardant Health expanding its liquid biopsy portfolio with enhanced genomic profiling applications for solid tumors. Exact Sciences strengthened its molecular oncology diagnostics pipeline through expanded precision cancer testing capabilities. Roche introduced advanced companion diagnostic solutions supporting precision oncology. Illumina expanded NGS applications for comprehensive oncology genomic profiling.

Short Conclusion

• The bladder cancer diagnostics market is positioned for sustained growth driven by the convergence of disease burden, technological innovation, and precision medicine. The transition from invasive procedures toward integrated non-invasive and molecular diagnostic approaches represents a fundamental shift in urological oncology. While challenges related to high costs, biomarker sensitivity, and regulatory requirements persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with bladder cancer diagnostics evolving into a critical component of precision oncology, supporting early detection, recurrence monitoring, treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Bladder Cancer Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Disease Overview
• 3.3 Disease Evolution and Diagnostic Landscape
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Disease Prevalence Analysis
• 3.8 Diagnosed Patient Population Analysis
• 3.9 Bladder Cancer Diagnostic Testing Volume Analysis
• 3.10 Patient Diagnostic Pathway Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Urine-Based Molecular Diagnostics
• 6.4 Artificial Intelligence in Bladder Cancer Diagnostics
• 6.5 Liquid Biopsy Technologies
• 6.6 Biomarker Discovery
• 6.7 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Bladder Cancer Diagnostics Market Landscape Analysis

• 8.1 Analysis by Diagnostic Modality
  • 8.1.1 Cystoscopy
  • 8.1.2 Urine-Based Diagnostics
  • 8.1.3 Histopathology
  • 8.1.4 Molecular Diagnostics
  • 8.1.5 Imaging Diagnostics
• 8.2 Analysis by Technology
  • 8.2.1 Immunohistochemistry (IHC)
  • 8.2.2 Fluorescence In Situ Hybridization (FISH)
  • 8.2.3 Polymerase Chain Reaction (PCR)
  • 8.2.4 Next-Generation Sequencing (NGS)
  • 8.2.5 Immunoassays
• 8.3 Analysis by Biomarker
  • 8.3.1 NMP22
  • 8.3.2 Bladder Tumor Antigen (BTA)
  • 8.3.3 UroVysion FISH
  • 8.3.4 Cytokeratin-Based Biomarkers
  • 8.3.5 Other Biomarkers
• 8.4 Analysis by Clinical Application
  • 8.4.1 Screening
  • 8.4.2 Initial Diagnosis
  • 8.4.3 Recurrence Monitoring
  • 8.4.4 Treatment Selection
  • 8.4.5 Disease Surveillance

9. Global Bladder Cancer Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments
  • 9.1.2 Reagents & Consumables
  • 9.1.3 Software
• 9.2 By Technology
  • 9.2.1 Immunohistochemistry (IHC)
  • 9.2.2 Fluorescence In Situ Hybridization (FISH)
  • 9.2.3 Polymerase Chain Reaction (PCR)
  • 9.2.4 Next-Generation Sequencing (NGS)
  • 9.2.5 Immunoassays
  • 9.2.6 Other Technologies
• 9.3 By End User
  • 9.3.1 Hospitals
  • 9.3.2 Diagnostic Laboratories
  • 9.3.3 Specialty Urology Clinics
  • 9.3.4 Academic & Research Institutes

10. Global Bladder Cancer Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Bladder Cancer Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Abbott Laboratories
  • 13.2.1 Company Overview
  • 13.2.2 Financials
  • 13.2.3 Product Portfolio
  • 13.2.4 Recent Developments
• 13.3 Danaher Corporation
  • 13.3.1 Company Overview
  • 13.3.2 Financials
  • 13.3.3 Product Portfolio
  • 13.3.4 Recent Developments
• 13.4 Thermo Fisher Scientific Inc.
  • 13.4.1 Company Overview
  • 13.4.2 Financials
  • 13.4.3 Product Portfolio
  • 13.4.4 Recent Developments
• 13.5 Agilent Technologies, Inc.
  • 13.5.1 Company Overview
  • 13.5.2 Financials
  • 13.5.3 Product Portfolio
  • 13.5.4 Recent Developments
• 13.6 QIAGEN N.V.
  • 13.6.1 Company Overview
  • 13.6.2 Financials
  • 13.6.3 Product Portfolio
  • 13.6.4 Recent Developments
• 13.7 Illumina, Inc.
  • 13.7.1 Company Overview
  • 13.7.2 Financials
  • 13.7.3 Product Portfolio
  • 13.7.4 Recent Developments
• 13.8 Bio-Rad Laboratories, Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Financials
  • 13.8.3 Product Portfolio
  • 13.8.4 Recent Developments
• 13.9 Sysmex Corporation
  • 13.9.1 Company Overview
  • 13.9.2 Financials
  • 13.9.3 Product Portfolio
  • 13.9.4 Recent Developments
• 13.10 Leica Biosystems
  • 13.10.1 Company Overview
  • 13.10.2 Financials
  • 13.10.3 Product Portfolio
  • 13.10.4 Recent Developments
• 13.11 bioMerieux
  • 13.11.1 Company Overview
  • 13.11.2 Financials
  • 13.11.3 Product Portfolio
  • 13.11.4 Recent Developments
• 13.12 Siemens Healthineers AG
  • 13.12.1 Company Overview
  • 13.12.2 Financials
  • 13.12.3 Product Portfolio
  • 13.12.4 Recent Developments
• 13.13 Guardant Health, Inc.
  • 13.13.1 Company Overview
  • 13.13.2 Financials
  • 13.13.3 Product Portfolio
  • 13.13.4 Recent Developments
• 13.14 Exact Sciences Corporation
  • 13.14.1 Company Overview
  • 13.14.2 Financials
  • 13.14.3 Product Portfolio
  • 13.14.4 Recent Developments
• 13.15 Fujifilm Holdings Corporation
  • 13.15.1 Company Overview
  • 13.15.2 Financials
  • 13.15.3 Product Portfolio
  • 13.15.4 Recent Developments

14. Global Bladder Cancer Diagnostics Market Commercial Forecast Analysis

• 14.1 Cystoscopy Systems
• 14.2 Urine-Based Diagnostic Tests
• 14.3 Histopathology-Based Diagnostics
• 14.4 Fluorescence In Situ Hybridization (FISH) Tests
• 14.5 Molecular Diagnostic Tests
• 14.6 Next-Generation Sequencing (NGS)-Based Tests
• 14.7 Bladder Cancer Biomarker Tests

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends